Humoral alloimmunity

SUNDAY 24 SEPTEMBER 2017 | 09:00-12.50

CHAIRS:  Fritz Diekmann, Berlin, Germany
               Ondrej Viklicky, Prague, Czech Republic


09:00-10:40            SESSION 1 

  • Basics of the HLA system
    Caner Süsal, Heidelberg, Germany
  • External validity and variability of solid phase results
    Jürg Steiger, Basel, Switzerland
  • HLA single epitope matching become real?
    Frans Claas, Leiden, The Netherlands
  • Preformed HLA DSAs and outcomes
    Christophe Legendre, Paris, France
  • De novo HLA-DSAs and hard outcomes. How to determine risk (class, number, complement activation?)
    Hans J.W. de Fijter, Leiden, The Netherlands


10:40 - 11:00           Break     


11:00-12:50            SESSION 2 

  • Alloimmunity trough non-HLA, the human knock out experiment
    Rainer Oberbauer, Vienna, Austria
  • Complement blockade and outcomes – novel approaches beyond eculizumab
    Georg Böhmig, Vienna, Austria
  • Treatment of ABMR features in management biopsies
    Ondrej Viklicky, Praha, Czech Repuplic
  • Underlying mechanisms of spontaneous operational tolerance
    Annick Massart, Brussels, Belgium



OBJECTIVES | To provide an overview and offer specific solutions for the ‘complicated’/sensitized patient. Solutions range from individualization through omics technologies to bioinformatics approaches.

TARGET AUDIENCE | Transplant surgeons and physicians, nephrologist, immunologists at all stages of training and expertise.


EKITA is the kidney section of ESOT and deals with all aspects of renal transplantation. As a European platform, EKITA supports research, education and clinical work in this area. Furthermore, EKITA is highly ambitious in preparing policies and creating transnational interactions to advance renal allografting in all European member states.

GOALS |The main goal of EKITA is to improve quality of life of people with ESRD by advancing all aspects of kidney transplantation.

AIM |The ultimate aim of EKITA is the optimization of renal transplantation trough activities in research, education, clinical collaboration and health policy.